EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease

Satomi Okada iD, Daisuke Muraoka iD, Kiyoshi Yasui, Isao Tawara, Ayumi Kawamura, Sachiko Okamoto, Junichi Mineno, Naohiro Seo iD, Hiroshi Shiku, Susumu Eguchi, Hiroaki Ikeda iD

Cancer Science · 2023

DOI: 10.1111/cas.15954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Satomi Okada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: Neoplasms, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive immunotherapy using genetically engineered patient‐derived lymphocytes to express tumor‐reactive receptors is a promising treatment for malignancy. However, utilization of autologous T cells in this therapy limits the quality of gene‐engineered T cells, thereby inhibiting the timely infusion of the cells into patients. In this study, we evaluated the anti‐tumor efficacy and the potential to induce graft‐versus‐host disease (GVHD) in T cell receptor (TCR) gene‐engineered allogeneic T cells that downregulate the endogenous TCR and HLA class I molecules with the aim of developing an “off‐the‐shelf” cell product with expanded application of genetically engineered T cells. We transduced human lymphocytes with a high‐affinity TCR specific to the cancer/testis antigen NY‐ESO‐1 using a novel retrovirus vector with siRNAs specific to the endogenous TCR (siTCR vector). These T cells showed reduced expression of endogenous TCR and minimized reactivity to allogeneic cells in vitro. In non‐obese diabetic/SCID/γc null mice, TCR gene‐transduced T cells induced tumor regression without development of GVHD. A lentivirus‐based CRISPR/Cas9 system targeting β‐2 microglobulin in TCR gene‐modified T cells silenced the HLA class I expression and prevented allogeneic CD8 + T cell stimulation without disrupting their anti‐tumor capacity. This report is the first demonstration that siTCR technology is effective in preventing GVHD. Adoptive cell therapy with allogeneic T cells engineered with siTCR vector may be useful in developing an “off‐the‐shelf” therapy for patients with malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationMiceAnimalsHumansRNA, Small InterferingAllogeneic CellsMice, SCIDReceptors, Antigen, T-CellGenes, T-Cell ReceptorImmunotherapy, Adoptive

Stichwörter der Autor:innen

T cell receptor gene therapyadoptive cell therapyallogeneic cellsendogenous T cell receptorhuman leukocyte antigen

Substanzen

RNA, Small InterferingReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan.
  • Takara Bio Inc., Shiga, Japan.
  • Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Mie, Japan.

ORCID-Profile: Satomi Okada, Daisuke Muraoka, Naohiro Seo, Hiroaki Ikeda

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Okada, S., Muraoka, D., Yasui, K., Tawara, I., Kawamura, A., Okamoto, S., Mineno, J., Seo, N., Shiku, H., Eguchi, S., & Ikeda, H. (2023). T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease. Cancer Science. https://doi.org/10.1111/cas.15954

Vancouver

Okada S, Muraoka D, Yasui K, Tawara I, Kawamura A, Okamoto S, et al. T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease. Cancer Science. 2023. doi:10.1111/cas.15954

BibTeX
@article{Okada2023,
  author = {Okada, Satomi and Muraoka, Daisuke and Yasui, Kiyoshi and Tawara, Isao and Kawamura, Ayumi and Okamoto, Sachiko and Mineno, Junichi and Seo, Naohiro and Shiku, Hiroshi and Eguchi, Susumu and Ikeda, Hiroaki},
  title = {T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15954}
}
Kostenlos starten →